GBT’s AI-Driven

Human Vitals qTerm Device Patent Received Notice of Allowance

“We are glad to announce that our qTerm, AI-driven human vitals measurements device, non-provisional patent has received a notice of allowance and is expected to be granted within the next upcoming months. This technology is planned to be marketed and sold for personal and clinics usage and also targeting the telemedicine arena. We consider our qTerm Device intellectual property as one of our major patents and plan to expand its protection along with improving its technology, in efforts to create an intelligent, personal health assistant for everyone” stated Danny Rittman, the Company’s CTO.



Leave a Replay

Related Posts

Sign up for our Newsletter

if you want to keep…. to our newsletter or follow our social media

DISCLAIMER: Certain statements contained in this website may constitute forward-looking statements Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website ( In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors. The forward-looking statements included in this website represent the Company’s views as of the date of this release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of the release.